Visterra, Inc. Announces Appointment Of John Weidenbruch As General Counsel

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Visterra, Inc., a clinical-stage biotechnology company that uses its proprietary technology platform to identify unique disease targets and design novel therapeutics for infectious diseases, today announced that it has appointed John Weidenbruch as General Counsel and Secretary of the Board of Directors.

Suggested Articles

Just three days after Daiichi Sankyo’s Xospata challenger scored approval in Japan for a form of acute myeloid leukemia, the FDA has declined to clear the drug…

Martin Shkreli settled a lawsuit he filed against his former Retrophin colleagues, claiming they “unceremoniously and illegally” ousted him in 2014.

The appointment ends a 20-year stint at Theravance Biopharma and its parent company that culminated in Sharath Hegde rising to head of research.